Hematologic Disorders Associated with Hepatitis C Virus Infection and Their Management

Dieterich, Douglas T.; Spivak, Jerry L.
August 2003
Clinical Infectious Diseases;8/15/2003, Vol. 37 Issue 4, p533
Academic Journal
More than 4 million people in the United States are infected with hepatitis C virus (HCV). During the next 20-30 years, the burden of HCV-related mortality and morbidity will likely double. To date, the most effective treatment for chronic HCV infection is the combination of either interferon (IFN)-α or pegylated IFN-α and ribavirin. For a sustained virologic response, treatment adherence and dose maintenance are essential. However, both IFN-α and ribavirin induce hematologic toxicity, such as anemia, neutropenia, and thrombocytopenia, which can compromise treatment adherence and dose maintenance and could, therefore, potentially influence outcomes. Although there are currently no approved treatments for hematologic complications of HCV therapy, studies have shown that hematopoietic growth factors can provide significant benefits. This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients.


Related Articles

  • Chronic Hepatitis C in the United States. Deresinki, Stan // Clinical Infectious Diseases;10/15/2006, Vol. 43 Issue 8, pvi 

    The article presents the abstract of the paper "The Prevalence of Hepatitis C virus infection in the United States, 1999 Through 2002," by G.L. Armstrong and colleagues.

  • CORRECTION.  // Annals of Internal Medicine;9/6/2005, Vol. 143 Issue 5, p395 

    Presents a correction to an article on patient-to-patient transmission of hepatitis C virus, published previously in the periodical "Annals of Internal Medicine."

  • Hepatitis C Virus Infection: Immune Responsiveness and Interferon-a Treatment. Jirillo, E.; Pellegrino, N.M.; Piazzolla, G.; Caccavo, D.; Antonaci, S. // Current Pharmaceutical Design;Jan2000, Vol. 6 Issue 2, p169 

    Hepatitis C virus (HCV) is responsible for most cases of posttransfusion hepatitis and sporadic or community-acquired non-A, non-B hepatitis. Different generations of enzyme-linked immunosorbent assay have been generated for detecting antibodies to HCV epitopes. HCV-RNA quantitative analysis has...

  • Biological and Clinical Significance of Endotoxemia in the Course of Hepatitis C Virus Infection. Caradonna, L.; Mastronardi, M.L.; Magrone, T.; Cozzolongo, R.; Cuppone, R.; Manghisi, O.G.; Caccavo, D.; Pellegrino, N.M.; Amoroso, A.; Jirillo, E.; L. Amati, E. // Current Pharmaceutical Design;May2002, Vol. 8 Issue 11, p995 

    Endotoxins or lipopolysaccharides (LPS), major components of the cell wall of Gram-negative bacteria, once released from the bacterial outer membrane bind to specific receptors and, in particular, to a membrane-bound receptor, the CD14 (mCD14) and the toll-like receptor 4 present on monocytes /...

  • Host Background Factors Contributing to Hepatitis C Virus Clearance. M.G. Isaguliants; N.N. Ozeretskovskaya // Current Pharmaceutical Biotechnology;Jun2003, Vol. 4 Issue 3, p185 

    This review is an attempt to characterize the host in the earliest events of hepatitis C virus (HCV) infection before the on-set of adaptive immune response. Host meets the replicating HCV with innate immune response in the form of proinflammatory cytokine production, activation of natural...

  • Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling. A. Lahm; A. Yagnik; A. Tramontano; U. Koch // Current Drug Targets;Aug2002, Vol. 3 Issue 4, p281 

    Hepatitis C virus (HCV), a member of the Flaviviridae family, has been recognised to be responsible for both parenterally transmitted and sporadic non-A and non-B hepatitis affecting 1-3% of the world population. HCV is a positive stranded RNA virus encoding a single polyprotein which contains...

  • Correction.  // New England Journal of Medicine;02/01/2001, Vol. 344 Issue 5, p392 

    A correction to the article "Patient-to-Patient Transmission of Hepatitis C Virus during Colonoscopy," that appeared in the July 24, 1997 issue, is presented.

  • What's the fuss about Hepatitis C? Pinette, Gilles // Windspeaker;May2002, Vol. 20 Issue 1, p21 

    Examines the epidemiology of hepatitis C virus. Symptoms and diagnosis; Treatment; Prevention.

  • Cost of interferon-alfa for chronic hepatitis C. Sadovsky, Richard // American Family Physician;6/1/1998, Vol. 57 Issue 11, p2824 

    Reports on the annual mortality rate of Americans who have hepatitis C virus infection with reference to the amount of persons who develop this infection. How hepatitis C can be considered; Effective use of the treatment with interferon-alfa; Circumstances surrounding the extension treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics